Page 69 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article INDIANAPOLIS, April 11, 2021 /PRNewswire/  Eli Lilly and Company (NYSE: LLY) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo ® (selpercatinib) demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal (GI) malignancies. The data were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021. We are excited to broaden the body of evidence for Retevmo in RET fusion-positive cancers beyond lung and thyroid tumors, said David Hyman, M.D., chief medical officer, oncology at Lilly. These encouraging outcomes, including in difficult-to-treat GI malignancies, support a growing body of evidence that

United statesVivek subbiahKevin hernDavid hymanEli lillyTracy henriksonUniversity of texas md anderson cancer centerCancer medicine divisionDrug administrationLilly united statesExchange commissionAmerican association for cancer researchLilly research laboratoriesInvestigational cancer therapeutics departmentClinical centerCancer research